(0.32%) 5 116.44 points
(0.30%) 38 355 points
(0.37%) 15 987 points
(-0.98%) $83.03
(5.25%) $2.02
(0.29%) $2 354.00
(0.42%) $27.65
(4.17%) $960.55
(-0.27%) $0.932
(-0.45%) $10.97
(-0.56%) $0.796
(1.63%) $93.37
Quarter results today
(bmo 2024-04-29)
Expected move: +/- 13.47%
@ $14.40
発行日: 24 4月 2024 @ 04:24
リターン: -6.56%
前回のシグナル: 4月 24 - 01:01
前回のシグナル:
リターン: -0.17 %
Live Chart Being Loaded With Signals
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases...
Stats | |
---|---|
本日の出来高 | 1.34M |
平均出来高 | 3.46M |
時価総額 | 2.08B |
EPS | $0 ( 2024-02-28 ) |
次の収益日 | ( $-0.0400 ) 2024-06-14 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 149.50 |
ATR14 | $0.0210 (0.16%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-13 | Lonial Sagar | Sell | 5 000 | Common Stock |
2024-03-12 | Charney Laurence N | Sell | 22 000 | Common Stock |
2024-02-14 | Power Sean A | Buy | 0 | |
2024-01-05 | Charney Laurence N | Sell | 17 500 | Common Stock |
2024-01-06 | Weiss Michael S | Buy | 1 001 908 | Common Stock |
INSIDER POWER |
---|
83.58 |
Last 94 transactions |
Buy: 12 977 390 | Sell: 1 920 924 |
ボリューム 相関
TG Therapeutics Inc 相関
10 最も負の相関 | |
---|---|
AMGN | -0.942 |
NAKD | -0.939 |
STAB | -0.936 |
TUEM | -0.935 |
LGMK | -0.934 |
PROC | -0.933 |
ORPH | -0.932 |
AHPI | -0.931 |
PCSA | -0.928 |
DBGI | -0.92 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
TG Therapeutics Inc 相関 - 通貨/商品
TG Therapeutics Inc 財務諸表
Annual | 2023 |
収益: | $233.66M |
総利益: | $219.11M (93.77 %) |
EPS: | $0.0893 |
FY | 2023 |
収益: | $233.66M |
総利益: | $219.11M (93.77 %) |
EPS: | $0.0893 |
FY | 2022 |
収益: | $2.79M |
総利益: | $2.52M (90.48 %) |
EPS: | $-1.510 |
FY | 2021 |
収益: | $6.69M |
総利益: | $5.90M (88.19 %) |
EPS: | $-2.63 |
Financial Reports:
No articles found.
TG Therapeutics Inc
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。